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ABSTRACT
BACKGROUND: Autosomal recessive mutations in the nuclear Twinkle (C10orf2) gene cause
a mitochondrial DNA depletion syndrome (MDS) characterized by early onset
hepatoencephalopathy.
METHODS: We report a severe, early onset encephalopathy and multisystem failure case
caused by novel recessive Twinkle gene mutations. Patient clinical, laboratory, and path-
ological features are reported and Twinkle-associated MDS literature reviewed.
RESULTS: Typical presentation includes symptom onset before age six months, failure to
thrive, psychomotor regression, epileptic encephalopathy, sensory axonal neuropathy,
cholestatic liver dysfunction, and occasionally, renal tubulopathy, movement disorders,
and ophthalmoplegia. Death is typical before age four years.
CONCLUSIONS: In the differential diagnosis of early onset encephalopathy and multisystem
failure, MDS should be considered.
© 2018 Elsevier Inc. All rights reserved.
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Introduction
Mitochondrial depletion syndromes (MDS) are com-
prised of autosomal recessive disorders caused by muta-
tions in nuclear genes encoding for key enzymes
involved in mitochondrial DNA (mtDNA) replication and/
or maintenance. These mutations result in decreased
mtDNA copy number, leading to impaired energy produc-
tion in various tissues.
The C10orf2 gene, also called PEO1 or Twinkle, encodes
the mtDNA replicative Twinkle helicase—important for
mtDNA replication. Dominant mutations in the Twinkle
gene can cause multiple mtDNA deletions and result in
chronic progressive external ophthalmoplegia or
mitochondrial myopathy. Recessive Twinkle mutations
cause mtDNA depletion.1
MDS are phenotypically heterogeneous and manifest
clinically as early onset encephalopathy, hepatoencephal-
opathy, encephalomyopathy, infantile onset spinocerebel-
lar ataxia, or Perrault syndrome.2,3 The hepatocerebral
form of MDS is associated with mutations in Twinkle,
POLG1, DGUOK, and MPV17. MDS associated with POLG1
is known as Alpers-Huttenlocher (Alpers) syndrome.
We describe a child with severe, early onset encepha-
lopathy and multisystem failure caused by recessive
Twinkle gene mutations that have never been docu-
mented before. We also review the literature on Twinkle-
associated MDS.
Patient description
This girl was born vaginally at 38+5 weeks
gestation to a 32-year-old G4P3 mother, on venlafaxine and
bupropion throughout pregnancy, and a healthy 33-year-old
father. The parents are Caucasian and non-consanguineous.
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There were four healthy siblings. Intrauterine growth restric-
tion was noted at 32 weeks gestation. Birth weight was
2.63 kg (5th percentile). She had poor oromotor coordination
from birth, requiring gastrostomy tube feeding by age four
months.
At two months of age, weight, length, and head cir-
cumference were all less than the third percentile. Exam-
ination of extraocular movements was suggestive of
internuclear ophthalmoplegia. Visual ﬁxation was incon-
sistent. Severe hypotonia with signiﬁcant head lag was
present. Deep tendon reﬂexes were absent. Episodes of
nonepileptic choreiform tongue movements were
observed. A prolonged generalized seizure occurred in
the context of hyponatremia (Na 117 mmol/L).
Initial laboratory investigations at age two months
revealed a mild raised anion gap metabolic acidosis. By age
three months, serum lactate was mildly elevated to 5 mmol/L
(normal < 2.8). Urine amino acids revealed a generalized
aminoaciduria. Plasma amino acids, ammonia, urine organic
acids, plasma acylcarnitine proﬁle, transferrin isoelectric
focusing, and very long chain fatty acids were normal. Crea-
tine kinase was normal. Initial liver function testing revealed
mild elevations in alanine aminotransferase (ALT) 46 U/L
(normal  33), aspartate aminotransferase (AST) 61 U/L
(normal  32), gamma-glutamyltransferase (GGT) 467 U/L
(normal  204), and lactate dehydrogenase 535 U/L (normal
< 300). Serum alpha-fetoprotein level was elevated at age
3.5 months (488 ug/L; normal  5).
The presence of proteinuria, elevated urine/microalbu-
min/creatinine ratio (167 mg/mmol creatinine; normal 0
to 2.8), elevated urine pH (>9.0), and ongoing need for
oral sodium and bicarbonate supplementation were sug-
gestive of a tubular nephropathy.
Abdominal ultrasound revealed mild splenomegaly, and
chest x-ray showed thymic hypoplasia. Echocardiogram,
electrocardiogram, brain magnetic resonance imaging (MRI)
were normal initially. Nerve conduction studies (motor: tib-
ial and peroneal, sensory; median, radial, ulnar, superﬁcial
peroneal, and sural) showed absent sensory responses and
normal motor responses. Repetitive nerve stimulation was
normal. Needle electromyography showed myopathic units.
Electroencephalogram revealed bilateral, independent tem-
poral interictal epileptiform discharges.
By age four months, she developed stridor requiring
supraglottoplasty for laryngomalacia; hypertension, treated
with amlodipine; bilateral asymmetric ptosis, not responsive
to pyridostigmine trial; and refractory status epilepticus
requiring pentobarbital infusion. She developed severe lactic
acidosis, refractory to sodium bicarbonate boluses. On the
last day of life, serum lactate was persistently elevated above
15 mmol/L. Cerebrospinal ﬂuid (CSF) revealed elevated lac-
tate 45 mmol/L (normal 0.62-2.10), pyruvate 0.25 mmol/L
(normal 0.06-0.22), and lactate/pyruvate ratio 182 (normal
10-25). A mild increase in concentration of most amino acids
was noted in the CSF, which can be secondarily increased in
all conditions with lactic acidosis and hyperammonemia.
Liver function testing revealed marked elevations in ALT
209 U/L, AST 306 U/L, ALP 605 U/L (normal  449), GGT
874 U/L, ammonia 90 umol/L (normal 11-48), and INR 3.4
(normal 0.9-1.1), as well as low Klaus Fibrinogen 0.85 g/L
(normal 2-4) and albumin 19 g/L (normal 38-54). Repeat
brain MRI at four months demonstrated interval develop-
ment of mild cerebral atrophy. MR spectroscopy was normal.
Following discussion with family, care was withdrawn and
the patient passed away at age four months.
Autopsy revealed severe microvesicular steatosis of
the liver tissue with ascites and bilateral pulmonary
edema. Muscle histology demonstrated type 1 ﬁber pre-
dominance, with signiﬁcant size variability in the muscle
ﬁbers and increases in sarcoplasmic lipid droplets and
internal nuclei. Electron microscopy showed structurally
abnormal mitochondria, with marked vacuolation, disar-
ray of the cristae, and a close association between abnor-
mal mitochondria and the lipid droplets. There was slight
evidence of ﬁber necrosis and inﬂammatory inﬁltrate.
Ragged red and blue ﬁbers were not evident through
Gomori trichrome staining and NADH-TR, respectively.
There were a few scattered cox-negative ﬁbers. Numer-
ous ﬁbers indicated an increase in oil red O staining.
Respiratory chain enzyme studies revealed decreased
activity of all mitochondrial respiratory chain complexes.
Central nervous system neuropathological examination
revealed widespread “metabolic” encephalopathic
changes, characterized by neuronal loss, secondary glio-
sis, focal mineralization of thalamic neurons, and astro-
cytic changes reminiscent of Alzheimer type II cells.
Chromosomal microarray was performed initially with
normal results. Subsequently, a comprehensive next gen-
eration sequencing panel of 183 genes associated with
muscular dystrophy and myopathy revealed two hetero-
zygous novel variants in the C10orf2 gene. The ﬁrst vari-
ant, c.853C>T, was reportedly the type expected to be
pathogenic and results in change of an arginine residue
to a stop codon at amino acid position 285 (p.Arg285Ter),
predicted to cause premature truncation of the protein.
The second variant, c1592+4A>G is an intronic splice site
variant, resulting in change from an adenine to a guanine
residue located at c.1592+4 and was predicted to alter
the exon 3 donor site with potential to alter splicing. The
data were insufﬁcient for deﬁnitive classiﬁcation and the
variant classiﬁed as of unknown signiﬁcance. Sanger
sequencing conﬁrmed the results. Parental testing
revealed the p.R285* variant was paternally and the
c.1592+4A>G variant maternally inherited.
Discussion
We describe the clinical, laboratory, pathologic and
molecular features of a patient with two novel heterozy-
gous mutations in the Twinkle gene, presenting with
early onset encephalopathy, status epilepticus, and liver
failure, resulting in death at age four months.
Only ten patients have been previously reported with
MDS caused by autosomal recessive Twinkle mutations, with
survival ranging from three months to 4.5 years (Table).4-8
Commonly reported clinical features of failure to
thrive, severe hypotonia, seizures, and abnormal eye
movements were represented in our patient. Dyskine-
sias5,8 and ataxia5 have been reported in a subset of
patients. These features presented after a variable period
of normal psychomotor development, with symptom
onset before age six months in all reported patients. Until
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Table.
Comparison of Clinical Features in Patient with Twinkle-Associated Mitochondrial DNA Depletion Syndrome
Case Symptom Onset Survival Neurological Features
Non-Neurological
Features MRI Brain Electrophysiology Mutation(s) Ref
1 Neonatal 3 years Neonatal: Axial hypotonia/
peripheral hypertonia,
developmental delay,
muscle atrophy (with ele-
vated CK)
10 months: seizures,
areﬂexia
Neonatal: mild hepatic
dysfunction, lactic
acidosis.
6 months: subdural col-
lection, mild ventricu-
lar dilatation
N/A Homozygous c.1370C>T
(p.Thr457Ile)
(ﬁrst cousin of cases 2
and 3)
[3]
2 Not reported 2 years Axial hypotonia, seizures,
peripheral sensory neu-
ropathy, abnormal eye
movements.
Failure to thrive, mild
liver insufﬁciency, ele-
vated lactate.
N/A N/A Homozygous c.1370C>T
(p.Thr457Ile)
(sibling of case 3)
[3]
3 Not reported 2 years Axial hypotonia, seizures,
peripheral sensory neu-
ropathy, abnormal eye
movements.
Failure to thrive, mild
liver insufﬁciency, ele-
vated lactate.
N/A N/A Homozygous c.1370C>T
(p.Thr457Ile)
(sibling of case 2)
[3]
4 6 months 4.5 years 6 months: Abnormal eye
movements,
8 months: Hypotonia,
psychomotor regression
13 months: Poor visual
ﬁxation, ophthalmopare-
sis, areﬂexia
18 months: Hearing
impairment
3.5 years: Ataxia, distal
amyotrophy, extensor
plantar responses
4.5 years: Epilepsia parti-
alis continua progressing
to status epilepticus
8 months: Feeding intol-
erance
12 months: Hepatic
dysfunction (transami-
nitis, elevated AFP and
LD), elevated lactate.
3.5 years: T2-hyperin-
tensities around 4th
ventricle, superior cer-
ebellar peduncle, and
dentate nuclei; cere-
bellar atrophy
EMG (30 months):
Absent sensory
responses
Auditory evoked
potentials (18
months): Abnormal
Compound heterozygous
c.1523A>G (p.
Tyr508Cys) and
c.952G>A (p.
Ala318Thr)
(sibling of case 5)
[4]
5 5 months Age 4 years at
time of report
(2012)
5 months: Abnormal eye
movements.
6 months: Hypotonia,
poor visual ﬁxation, ataxia
(suspected), areﬂexia,
athetosis
11 months: Dysphagia
25 months: Myoclonus
and epilepsia partialis
continua progressing to
refractory generalized
convulsive status epilepti-
cus
4 years: Ophthalmoparesis
11 months: Feeding
intolerance, failure to
thrive.
8.5 months:
Hepatic dysfunction
(transaminitis).
8.5 months: Normal EEG (8.5 months): Nor-
mal
EEG (25 months): Focal
irritation with general-
ization
EMG (8.5 months):
Absent sensory
responses
Compound heterozygous
c.1523A>G (p.
Tyr508Cys) and
c.952G>A (p.
Ala318Thr)
(sibling of case 4)
[4]
6 Neonatal 6 months 10 weeks: Dysconjugate
gaze, seizures
Neonatal: Hypoglycemia,
hyperammonemia.
10 weeks: Renal tubul-
opathy, hepatomegaly
and liver failure
4 days/10 weeks (with
MRS): Both normal
Visual and auditory
evoked potentials (10
weeks): Abnormal
Compound heterozygous
C85C>T (p.Arg29Ter)
and c1523A>G (p.
Tyr508Cys)
[5]
7 Unknown 3 months Limited information
available
Limited information
available. 3 months:
Renal tubulopathy, lac-
tic acidosis.
N/A N/A Homozygous c.1183T>C
(p.Phe395Leu)
(sibling of patient 8
and 9)
[6]
(continued on next page )
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Table (Continued)
Case Symptom Onset Survival Neurological Features
Non-Neurological
Features MRI Brain Electrophysiology Mutation(s) Ref
8 Neonatal 4 months 6 weeks: Irritability Neonatal: Jaundice, vom-
iting, feeding intoler-
ance, elevated lactate.
6 weeks: Hypoglyce-
mia, renal tubulopathy,
hepatic dysfunction
(mild transaminitis),
elevated tyrosine (uri-
nary succinylacetone
normal), lactic acidosis.
N/A N/A Homozygous c.1183T>C
(p.Phe395Leu)
(sibling of patient 7
and 9)
[6]
9 Neonatal 6 months 0-3 months: Irritability,
lethargy hypotonia, poor
suck/swallow, abnormal
visual behaviors
Neonatal: Hypoglycemia,
hepatic dysfunction
(hepatomegaly, mild
transaminitis, conju-
gated hyperbilirubine-
mia) newborn screen
positive for tyrosine-
mia (urinary succinyla-
cetone negative), renal
tubulopathy, failure to
thrive, feeding
intolerance.
3 months: Normal EEG (3 months): Dif-
fusely slow, poorly
organized background
Homozygous c.1183T>C
(p.Phe395Leu)
(sibling of patient 7
and 8)
[6]
10 Neonatal 21 months 5 months: Hypotonia, psy-
chomotor regression
7 months: Abnormal eye
movements, lingual dyski-
nesias
11 months: Chorea (upper
limbs, face), areﬂexia
12-21 months: Loss of
visual ﬁxation
0-5 months: Recurrent
vomiting
7 months: Failure to
thrive
1 year: Elevated AFP,
abnormal
glycosylation proﬁle
suggestive of type I
CDG
1 year (brain and spine):
Normal
EEG (1 year): Poorly
organized background
Auditory evoked
potentials (1 year):
Bilateral sensorineural
hearing loss.
EMG (1 year): Sensori-
motor neuropathy.
Compound heterozygous
c.316G>A (p.Lys106-
Glu)
and c.1181G>A (p.
Arg394His)
[7]
11 Neonatal 4 months 2 months: Irritability, severe
hypotonia, psychomotor
delay, dysconjugate gaze,
poor visual ﬁxation, lin-
gual dyskinesias, areﬂexia
4 months: Bilateral ptosis,
refractory status
epilepticus
Neonatal: Hypoglycemia,
failure to thrive.
Hyponatremia
2 months: Renal tubul-
opathy, lactic acidosis,
hepatic dysfunction
(mild transaminitis).
3 months: laryngoma-
lacia, hypertension.
4 months: Refractory
lactic acidosis, liver
failure.
2 months: Normal
4 months (with MRS):
Mild cerebral atrophy
EEG (2 months): Bilateral
independent temporal
discharges.
EEG (4 months): Multi-
ple independent spike
foci
EMG (2 months):
Absent sensory
responses; mild myo-
pathic features
EMG (4 months):
Unchanged
Compound heterozygous
c.853C>T (p.
Arg285Ter) and c1592
+4A>G
Our patient
Abbreviations: AFP, alpha-fetoprotein; CDG, congenital disorder of glycosylation; LD, lactate dehydrogenase; MRS, magnetic resonance spectroscopy.
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now, ptosis has been reported in other mitochondrial
disorders, but not Twinkle-associated MDS.
Common laboratory features include neonatal hypo-
glycemia and, later, lactic acidosis and cholestatic liver
dysfunction, as seen in our patient. In one patient
reported by Bouchereau et al., plasma and CSF lactate
remained normal and the patient had an abnormal glyco-
sylation proﬁle suggestive of congenital disorder of gly-
cosylation type I.8 Renal tubulopathy has been reported
in four patients, including ours.6,7
In previously reported patients, MRI ﬁndings ranged
from normal to cerebellar atrophy. In our patient, mild
cortical atrophy was present by four months. Electromy-
ography (EMG) ﬁndings were consistent, with sensory
neuropathy in the majority of reported patients.
Muscle biopsy ﬁndings were described in the patients
reported by Sarzi et al. and Hakonen et al.4,5 Pathology
included lipid accumulation and either decreased cox
staining or cox-negative ﬁbers, also seen in our patient.
Muscle pathology was normal at autopsy in the patient
reported by Goh et al. and one by Prasad et al., both pre-
senting with predominant hepatic and renal failure.6,7
Liver pathology has demonstrated micro- or macrovesic-
ular steatosis and cirrhosis in most patients. Mitochon-
drial DNA depletion was demonstrated in the patient
tissues reported by Sarzi et al. and Goh et al.4,6
Unfortunately, there is limited evidence for effectiveness of
supplements that have been used in other mitochondrial dis-
orders. However, mitochondrial transplantation has been
demonstrated to rescue mitochondrial respiratory function in
animal models of myocardial and liver ischemia, as well as in
cells harboring the mitochondrial DNA mutation MERRF
A8344G, and may present a therapeutic option in patients
withmitochondrial diseases in future.9
Conclusions
The typical presentation of autosomal recessive MDS is
characterized by early onset hepatoencephalopathy, failure to
thrive, psychomotor delay and/or regression, epileptic
encephalopathy, sensory axonal neuropathy, progressive liver
dysfunction, and in some patients, renal tubulopathy, move-
ment disorders, and ophthalmoplegia. As such, MDS should be
considered on the differential of early onset encephalopathy
and multisystem failure. The description of this patient and
the documentation of newmutations in the Twinkle gene is an
important contribution to the understanding of this complex
and severe neurodegenerative condition.
We thank the family for allowing us to present this case. Diane Love provided
valuable input on the ﬁnal draft of the manuscript.
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